NASDAQ: GYREGyre Therapeutics Inc Stock
$7.01-0.25 (-3.44%)
Updated Jul 7, 2026
GYRE Price
$7.01
Fair Value Price
-$1.77
Market Cap
$680.17M
52 Week Low
$5.44
52 Week High
$9.42
P/E
-87.63x
P/B
6.71x
P/S
5.44x
PEG
N/A
Dividend Yield
N/A
Revenue
$117.05M
Earnings
-$6.36M
Gross Margin
95.1%
Operating Margin
-1.78%
Profit Margin
-5.4%
Debt to Equity
0.25
Operating Cash Flow
$4M
Beta
1.31
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
GYRE Overview
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GYRE's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GYRE
Ranked#276 of 462
Ranked#276 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $247.72 | A | |
| $10.34 | A | |
| $16.22 | A |
Be the first to know about important GYRE news, forecast changes, insider trades & much more!
GYRE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GYRE scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GYRE ($7.01) is overvalued by 495.35% relative to our estimate of its Fair Value price of -$1.77 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GYRE ($7.01) is not significantly undervalued (495.35%) relative to our estimate of its Fair Value price of -$1.77 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GYRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more GYRE due diligence checks available for Premium users.
Valuation
GYRE fair value
Fair Value of GYRE stock based on Discounted Cash Flow (DCF)
Price
$7.01
Fair Value
-$1.77
Undervalued by
495.35%
GYRE ($7.01) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GYRE ($7.01) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GYRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GYRE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-87.63x
Industry
17.73x
Market
8.58x
GYRE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.71x
Industry
5.67x
GYRE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GYRE's financial health
Profit margin
Revenue
$22.5M
Net Income
-$8.7M
Profit Margin
-38.6%
GYRE's Earnings (EBIT) of -$2.09M... subscribe to Premium to read more.
Interest Coverage Financials
GYRE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$162.0M
Liabilities
$25.0M
Debt to equity
0.25
GYRE's short-term assets ($91.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GYRE's short-term assets ($91.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GYRE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GYRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.2M
Investing
-$3.1M
Financing
$21.0k
GYRE's operating cash flow ($4.32M)... subscribe to Premium to read more.
Debt Coverage Financials
GYRE vs Biotech Stocks
Gyre Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.